Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content ++ All dosages are for adults unless otherwise specified. For details on pediatric dosages, please refer to Chapter 167. ++ Abciximab (ReoPro): see table on antiplatelet agentsAcetazolamide (Diamox): see table on diuretics(Aldactone) Spironolactone: see table on diureticsAlfentanil (Alfenta): see table on opioidsAminocaproic acid (Amicar): see table on antifibrinolytics(Anectine) Succinylcholine: see table on neuromuscular blocking agents ++Table Graphic Jump Location|Download (.pdf)|PrintAnticholinergicsTachycardiaBronchodilationSedationAntisialagogueAtropine++++++++Scopolamine+++++++Glycopyrrolate (Robinul) (does not cross BBB)++++0+++ ++ See following table. ++Table Graphic Jump Location|Download (.pdf)|PrintAnticoagulants and ReversalDrugArgatrobanDirect thrombin inhibitor2 μg/kg/min infusion up to 10 μg/kg/min (HIT), 350 μg/kg IV over 2–5 min with 25 μg/kg/min infusion (PCI in patients with HIT)Antithrombin III (ATIII, Thrombate III)Binds coagulation factors, preventing formation of clotDetermine preinfusion (baseline) antithrombin III concentration and calculate initial (loading) dosage using following formula:Administer dose to increase antithrombin III concentration to a suggested level of 120% of normal using formulaEnoxaparin (Lovenox)Accelerates activity of antithrombin III30–40 mg SC bid (DVT prophylaxis), 1 mg/kg SC q12 h or 1.5 mg/kg SC q day (Tx of DVT), 1.5 mg/kg/dose SC q12 h (ACS)ProtamineCombines with heparin (strong acid) to form a stable complex (salt)1 mg protamine per mg of active heparinWarfarin (Coumadin)Inhibits factors 2, 7, 9, 10 and proteins C and S5 mg PO, and then maintenance of 2–10 mg PO for goal INR of 2–3++Table Graphic Jump Location|Download (.pdf)|PrintAntiemeticsDrugDose (IV)MechanismAnesthetic considerationsOndansetron (Zofran)4 mg (adults), 0.1 mg/kg (pediatrics) up to 4 mg5-HT3 receptor antagonistProlongs QT intervalHepatic clearanceGranisetron (Kytril)1 mg (adults), 10 μg/kg (pediatrics)5-HT3 receptor antagonistDolasetron (Anzemet)12.5 mg (adults), 0.35 mg/kg5-HT3 receptor antagonistDroperidol (Inapsine)1–2 μg/kg (adults), 0.1 mg/kg (pediatrics)DA antagonist, blocks release of NE, 5-HT, GABAProlongs QT interval (black box warning), hypotension, extrapyramidal effects, avoid in pheochromocytoma, avoid in patients receiving L-dopa therapyDexamethasone (Decadron)4–12 mgAntiemetic mechanism unclearAdminister with caution in patients with DMUseful if airway trauma during repeated intubationsUseful as antiemetic (4 mg)Metoclopramide (Reglan)0.25 mg/kgDA antagonist centrally, peripheral cholinomimeticAvoid in patients with pheochromocytomaCan cause extrapyramidal side effects, neuroleptic malignant syndromeDoes not affect gastric pHPromethazine (Phenergan)12.5–25 mgH1 receptor antagonistDA blockerPartial alpha-blockerRespiratory depressionCNS depressionRare neuroleptic malignant syndrome++Table Graphic Jump Location|Download (.pdf)|PrintAntifibrinolyticsDrugDosageMechanism of actionAminocaproic acid (Amicar)Acute bleeding: 4–5 g during the first hour, followed by 1 g/h for 8 h or until bleeding controlled (maximum daily dose: 30 g)Thrombocytopenia: 0.1 g/kg over 30–60 minBlocks activation of plasminogen to plasminAprotinin (Trasylol)2 million KIU (280 ... Your Access profile is currently affiliated with '[InstitutionA]' and is in the process of switching affiliations to '[InstitutionB]'. Please click ‘Continue’ to continue the affiliation switch, otherwise click ‘Cancel’ to cancel signing in. Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Username Error: Please enter User Name Password Error: Please enter Password Forgot Password? Forgot Username? Sign in via OpenAthens Sign in via Shibboleth